Conclusively, our findings emphasize that administering PCa patients with AR targeted therapies may result in increased SPINK1 levels accompanied by upregulation of NE markers, potentially promoting the development of treatment-related NEPC (Fig. 8). The gene discussed is SPINK1; the disease is posterior cortical atrophy.